Robotic versus laparoscopic Gastrectomy for gastric cancer: a systematic review and updated meta-analysis

BMC Surgery

Table 5 Systematic Review of Recurrence and Long-term Survivals

Author	Group	Stage	Chemotherapy	Follow-up (mo)	Recurrence	Survival (%)
Pugliese	LG	Any TNM₀	T₃ or any TN₊	53 (3–112)	8^a	3y–OS: 85; 5y–OS: 83^&
Pugliese	RG	Any TNM₀	T₃ or any TN₊	28 (2–44)	4^a	3y–OS: 78^&
Son T	LG	Any TNM₀	NR	70	3^b	5y–DFS: 91.2; 5y–OS: 91.1
Son T	RG	Any TNM₀	NR	70	3^b	5y–DFS: 90.2; 5y–OS: 89.5
Zhou	LG	Any TNM₀	Routinely^#	17(3–41)	28	1, 2, 3-OS: 87.3, 77.1, 69.9 3y–OS N₋:82.6, 3y–OS N₊:60.3
Zhou	RG	Any TNM₀	Routinely^#	17(3–41)	5	1, 2, 3-OS: 90.2, 78.1, 67.8 3y–OS N₋: 84.4, 3y–OS N₊: 57.5
Lee	LG	Any TNM₀	NR	75	NR	NSD
Lee	RG	Any TNM₀	NR	75	NR	NSD
Han	LG	cT_1-2N₀M₀	3 cases (4.4%)^$	19.3	0	NSD
Han	RG	cT_1-2N₀M₀	3 cases (4.4%)^$	22.7	0	NSD

Follow-up time were shown as median (range) or median only
DFS disease-free survival, OS overall survival, y year, N ₋ negative nodal metastasis, N ₊ positive nodal metastasis, NR not report, NSD only reported no significant difference between two groups without specific survival rate
^asome patients had mixed tumor recurrence, identified recurrence in LG: local (n = 2), peritoneum (n = 2), liver (n = 1), lung (n = 2), bone (n = 1); identified recurrence in RG: peritoneum (n = 1), liver (n = 1), bone (n = 1). &: for overall patients, 5y–OS N₋: 97%, 5y–OS N₊: 52%
^bLG, peritoneum (n = 2), lung (n = 1); RG, breast (n = 1), splenic hilum (n = 1), ovary (n = 1). #: 5-fluorouracil + oxaliplatin intravenous chemotherapy. $: because of advanced disease status after surgery

ISSN: 1471-2482